AZN - AstraZeneca PLC
LSE
->
Healthcare
->
Drug Manufacturers—General
Cambridge,
United Kingdom
Type: Equity
AZN price evolution
AZN
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $6916 | $7841 | $5840 | $4871 |
| Short term investments | $160 | $180 | $122 | $244 |
| Net receivables | $12622 | $12225 | $13552 | $11997 |
| Inventory | $5667 | $5337 | $5424 | $5292 |
| Total current assets | $25393 | $25594 | $25054 | $22501 |
| Long term investments | $1871 | $1695 | $1677 | $1290 |
| Property, plant & equipment | $10833 | $10616 | $10502 | $9700 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $104340 | $102293 | $101119 | $96086 |
| Current liabilities | ||||
| Accounts payable | $20463 | $19699 | $21541 | $19723 |
| Deferred revenue | ||||
| Short long term debt | $5410 | $6423 | $6389 | $6509 |
| Total current liabilities | $28566 | $28901 | $30542 | $28588 |
| Long term debt | $28235 | $28271 | $23260 | $23044 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $64742 | $64792 | $61953 | $58865 |
| Shareholders' equity | ||||
| Retained earnings | $1847 | -$212 | $1502 | -$434 |
| Other shareholder equity | $2164 | $2131 | $2088 | $2102 |
| Total shareholder equity | $39598 | $37501 | $39166 | $37221 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5840 | $1411 | $1461 | $7832 |
| Short term investments | $122 | $64 | $53 | $160 |
| Net receivables | $13552 | $11252 | $8795 | $5651 |
| Inventory | $5424 | $4699 | $8983 | $4024 |
| Total current assets | $25054 | $22593 | $26244 | $19544 |
| Long term investments | $1677 | $1142 | $1262 | $1147 |
| Property, plant & equipment | $10502 | $9449 | $10171 | $8917 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $47185 | |||
| Total investments | ||||
| Total assets | $101119 | $96483 | $105363 | $66729 |
| Current liabilities | ||||
| Accounts payable | $21541 | $19040 | $2824 | $2350 |
| Deferred revenue | ||||
| Short long term debt | $6389 | $1538 | $2892 | $2386 |
| Total current liabilities | $30542 | $26293 | $22594 | $20307 |
| Long term debt | $23260 | $23690 | $28888 | $17994 |
| Total noncurrent liabilities | $30784 | |||
| Total debt | ||||
| Total liabilities | $61953 | $59446 | $66095 | $51107 |
| Shareholders' equity | ||||
| Retained earnings | $1502 | $1495 | $3755 | $7323 |
| Other shareholder equity | $2088 | -$1604 | $130 | $2040 |
| Total shareholder equity | $39166 | $37058 | $39287 | $15622 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $12938 | $12679 | $12024 | |
| Cost of revenue | $2167 | $2198 | $2295 | |
| Gross Profit | $10771 | $10481 | $9729 | |
| Operating activities | ||||
| Research & development | $2911 | $2703 | $3352 | |
| Selling, general & administrative | $5020 | $4533 | $5468 | |
| Total operating expenses | $10038 | $9369 | $11720 | |
| Operating income | $2900 | $3310 | $304 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $469 | $620 | -$62 | |
| Interest expense | -$443 | -$413 | -$445 | |
| Net income | ||||
| Net income | $1927 | $2179 | $960 | |
| Income (for common shares) | $1927 | $2179 | $960 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $45811 | $44351 | $37417 | $26617 |
| Cost of revenue | $8040 | $8619 | $9799 | $5270 |
| Gross Profit | $37771 | $35732 | $27610 | $21347 |
| Operating activities | ||||
| Research & development | $10716 | $9529 | $8021 | $6094 |
| Selling, general & administrative | $18602 | $17653 | $9338 | |
| Total operating expenses | $37107 | $35388 | $21455 | |
| Operating income | $8704 | $8963 | $5343 | $5162 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $938 | -$792 | -$380 | $772 |
| Interest expense | -$1626 | -$1346 | -$776 | |
| Net income | ||||
| Net income | $5955 | $3288 | $112 | $3196 |
| Income (for common shares) | $5955 | $3288 | $112 | $3196 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | $1927 | $2179 | $960 | $1374 |
| Operating activities | ||||
| Depreciation | $1253 | $300 | $320 | $268 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $3085 | $2486 | $2380 | $3114 |
| Investing activities | ||||
| Capital expenditures | -$382 | -$417 | -$525 | -$319 |
| Investments | ||||
| Total cash flows from investing | -$2872 | -$2413 | -$1077 | -$1221 |
| Financing activities | ||||
| Dividends paid | -$17 | -$3033 | -$2 | -$1410 |
| Sale and purchase of stock | $5 | $6 | $21 | $4 |
| Net borrowings | -$1210 | $5896 | -$310 | -$1274 |
| Total cash flows from financing | -$1222 | $2028 | -$291 | -$2726 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1015 | $2055 | $1018 | -$852 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $5955 | $3288 | $112 | $3916 |
| Operating activities | ||||
| Depreciation | $1107 | $1098 | $4039 | $3149 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $10345 | $9808 | $5963 | $4799 |
| Investing activities | ||||
| Capital expenditures | -$1361 | -$1091 | -$1091 | -$2606 |
| Investments | ||||
| Total cash flows from investing | -$4064 | -$2960 | -$11058 | -$285 |
| Financing activities | ||||
| Dividends paid | -$4481 | -$4364 | -$3856 | -$3572 |
| Sale and purchase of stock | $33 | $29 | $29 | $30 |
| Net borrowings | -$1233 | -$1441 | $7654 | $1440 |
| Total cash flows from financing | -$6567 | -$6823 | $3649 | -$2203 |
| Effect of exchange rate | -$16 | -$20 | $12 | |
| Change in cash and equivalents | -$346 | -$55 | -$1508 | $2323 |
News
Fundamentals
| Market cap | $31.60T |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 3.08B |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 844.17 |
| Book/Share | 12.15 |
| Cash/Share | 2.24 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.58 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.89 |
| Quick ratio | 0.69 |